Novartis says high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose

This article was originally published here

The post hoc analysis from the pivotal Phase III IRIDIUM study—presented virtually at the European Respiratory Society (ERS) International Congress 2020— also showed the safety profile for high-dose

The post Novartis says high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose appeared first on Pharmaceutical Business review.